Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

doi:10.1097/QAD.0000000000004388

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.

AIDS (London, England) - 1 Apr 2026

Buzón-Martín Luis, Bernardino José I, Galindo Puerto María José, Martín-Torres Juan, Alemán Valls María Remedios, Torralba González de Suso Miguel, Díaz de Santiago Alberto, Fanjul Francisco, Rodríguez Adrián, Cabello Úbeda Alfonso, Pedrero-Tomé Roberto, Crusells Canales María José, Calzado Isbert Sonia, Aguilera García María, Hidalgo Tenorio Carmen, Morano Luis, Vinuesa García David, de Andrés David Carlos, Bernal Morell Enrique, Martínez Álvarez Rosa María, Cabello Clotet Noemí, Tiraboschi Juan, Gimeno García Alejandra, Vivancos María Jesús, Troya Jesús

Abstract excerpt

OBJECTIVES: Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI CAB+RPV with or without available genotypes in the Spanish RELATIVITY cohort. DESIGN: RELATIVITY...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotyping Techniques

Share to HIV Infections

Share to Pyridones

Share to Rilpivirine

Share to Spain

Share to Sustained Virologic Response

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 41183264
DOI: 10.1097/QAD.0000000000004388
PMCID: PMC12955951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.PMID 41183264Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read ↗

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countriesSemantic proximity Read ↗

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsSemantic proximity Read ↗

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.Semantic proximity Read ↗

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study.Semantic proximity Read ↗

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.Semantic proximity Read ↗

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.Semantic proximity Read ↗

Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in PolandSemantic proximity Read ↗

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsSemantic proximity Read ↗

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.Semantic proximity Read ↗

The Role of Prior HBV Infection and Resistance Mutations on the Efficacy of 3TC/DTG as a Maintenance TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.